Table 2

Inhaler prescriptions by comorbidity as recorded on electronic medical records, or as identified on radiology

Clinical parametersSAMA/SABALAMA/LABA+ICSP value
Electronic medical record of airway disease (n=334)
 Any COPD (n=307)32/45 (71%)28/31 (90%)247/270 (92%)0.001*
 Any bronchiectasis (n=106)11/45 (24%)7/31 (23%)88/270 (33%)0.364
 Any asthma (n=54)7/45 (16%)1/31 (3%)46/270 (17%)0.122
 Comorbidity breakdown
 COPD (alone) (n=181)23/45 (51%)22/31 (71%)136/270 (50%)0.008*
 COPD+bronchiectasis (n=87)6/45 (13%)5/31 (16%)76/270 (28%)
 COPD+asthma (n=34)3/45 (7%)1/31 (3%)30/270 (11%)
 Bronchiectasis (alone) (n=12)4/45 (9%)2/31 (7%)6/270 (2%)
 Bronchiectasis+asthma (n=2)1/45 (2%)0/31 (0%)1/270 (0%)
 Asthma (alone) (n=13)3/45 (7%)0/31 (0%)10/270 (4%)
 COPD+bronchiectasis+asthma (n=5)0/45 (0%)0/31 (0%)5/270 (2%)
Clinical comorbidities not recorded (n=12)5/45 (11%)1/31 (3%)6/270 (2%)
Radiology (n=335)
 Any bronchiectasis (n=90)11/38 (29%)10/30 (33%)69/267 (26%)0.587
 Any COPD (n=142)12/38 (32%)12/30 (40%)118/267 (44%)0.328
 Bronchiectasis (alone) (n=44)6/38 (16%)5/30 (17%)33/267 (12%)0.693
 COPD (alone) (n=96)7/38 (18%)7/30 (23%)82/267 (31%)
 COPD+Bronchiectasis (n=46)5/38 (13%)5/30 (17%)36/267 (14%)
 No COPD or Bronchiectasis (n=149)20/38 (53%)13/30 (43%)116/267 (44%)
  • P value obtained via χ2 or Fisher’s exact test (cases where cells values were <10).

  • *p<0.05.

  • COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonists; SABA, short-acting bronchodilator; SAMA, short-acting muscarinic antagonists.